PARIS and Waltham, MA – Feb. 13, 2023 – The growing prevalence of fatty liver disease in the U.S. has led the American Association for the Study of Liver Diseases (AASLD) to call for expanded use of ...
BOSTON, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of data at the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Katherine MacPhail is a reporter and editorial events programmer for STAT. Isabella is a chronic disease reporter writing about how the Trump administration is tackling the nation’s health epidemic — ...
Vebicorvir Phase 2 open-label study data demonstrate the contribution of core inhibition to deepen viral suppression; Oral presentation scheduled for November 14 at 10 am ET “Through our core ...
The American Association for the Study of Liver Diseases (AASLD), in partnership with the Infectious Diseases Society of America (IDSA) and in collaboration with the International Antiviral ...
Preclinical data shows strong, durable, and precise repression of HBV DNA across in vitro and in vivo models, offering a possible pathway to a functional cure DURHAM, N.C. & SEATTLE--(BUSINESS ...
The American Association for the Study of Liver Diseases (AASLD), in partnership with the Infectious Diseases Society of America (IDSA) and in collaboration with the International Antiviral ...
The American Association for the Study of Liver Diseases Foundation, the largest private supporter of liver disease research and training in the United States, today announced its investment of $3.42 ...
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that four abstracts have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The ...
Daix (France), Long Island City (New York, United States), November 3, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results